.jpeg)
2025-10-19 11:44:20
Sotorasib, a specific inhibitor of oral KRAS G12C launched by Amgen in the United States, was approved for marketing for the first time under the accelerated channel of the US FDA on May 28, 2021. It was first used to treat patients with KRAS Patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with G12C mutations mark the advent of oral targeted therapy for KRAS-mutated lung cancer.
2025-10-19 11:44:20
Rupitidine is only for intravenous injection. Check for particulate matter and discoloration before administration. Do not administer if observed. Rupitidine can be administered with or without an in-line filter. If an in-line filter is used, a polyethersulfone in-line filter with a pore size of 0.22 micron is recommended. Consider the use of a central venous catheter, especially in patients with limited venous access, to reduce the risk of extravasation.
